What Protalix BioTherapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 1 |
| Sells | 0 | 1 |
| Total trades | 0 | 2 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 56,000 |
| Disposed | 0 | 168 |
| Net activity | +0 | +55,832 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Bashan Dror | PRESIDENT AND CEO | Dec 19 | Open-market buy · P | +56,000 | $1.81 | +$101K | 188,516 |
| Bar-Shalev Amos | Director | Nov 18 | Open-market sale · S | −168 | $1.87 | −$314 | 0 |
| Bashan Dror | PRESIDENT AND CEO | Sep 03 | Grant / award · A | +195,000 | — | — | 2,344,418 |
| Naos Yaron | Sr. VP, Operations | Sep 03 | Grant / award · A | +25,000 | — | — | 225,817 |
| Bar-Shalev Amos | Director | Sep 03 | Grant / award · A | +7,500 | — | — | 7,500 |
| Boudes Pol F | Director | Sep 03 | Grant / award · A | +7,500 | — | — | 7,500 |
| Ben Zvi Shmuel | Director | Sep 03 | Grant / award · A | +7,500 | — | — | 7,500 |
| Schwartz Aharon | Director | Sep 03 | Grant / award · A | +7,500 | — | — | 7,500 |
| Elze Christian | Director | Sep 03 | Grant / award · A | +7,500 | — | — | 7,500 |
| Melincoff Gwen A | Director | Sep 03 | Grant / award · A | +7,500 | — | — | 7,500 |
| Forster Eliot | Director | Sep 03 | Grant / award · A | +7,500 | — | — | 7,500 |
| Schwartz Aharon | Director | Jun 10 | Open-market buy · P | +129,000 | $1.60 | +$206K | 303,000 |
| Rubin Eyal | Sr. VP and CFO | Sep 23 | Grant / award · A | +90,909 | — | — | 660,909 |
| Bashan Dror | PRESIDENT AND CEO | Apr 01 | Grant / award · A | +263,960 | — | — | 2,149,418 |
| Bashan Dror | PRESIDENT AND CEO | Oct 19 | Open-market buy · P | +16,129 | $1.41 | +$22.7K | 132,516 |
| Bashan Dror | PRESIDENT AND CEO | Oct 19 | Open-market buy · P | +48,387 | $1.40 | +$67.7K | 116,387 |
| Hayon Yael | VP, Research & Development | Aug 15 | Grant / award · A | +35,115 | — | — | 35,115 |
| Naos Yaron | Sr. VP, Operations | Aug 15 | Grant / award · A | +187,344 | — | — | 200,817 |
| Rubin Eyal | Sr. VP and CFO | Aug 15 | Grant / award · A | +201,903 | — | — | 570,000 |
| Bashan Dror | President and CEO | Aug 15 | Grant / award · A | +800,000 | — | — | 1,885,458 |
Loading...
